Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.46−0.09 (-15.97%)
Close on Nov 17, 2026Market cap $830.71KP/E –Yield –
Aptevo Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Aptevo Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.20M, up 9.0% year over year. For fiscal 2025 it was $14.54M, up 1.1% from the year before. Over ten years it grew -8.3% a year on average. The highest annual figure on record is $35.39M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.54M | +1.1% |
| FY2024 | Dec 31, 2024 | $14.38M | -16.0% |
| FY2023 | Dec 31, 2023 | $17.11M | -4.3% |
| FY2022 | Dec 31, 2022 | $17.88M | -5.9% |
| FY2021 | Dec 31, 2021 | $18.99M | +6.4% |
| FY2020 | Dec 31, 2020 | $17.85M | -27.9% |
| FY2019 | Dec 31, 2019 | $24.76M | -30.0% |
| FY2018 | Dec 31, 2018 | $35.39M | +21.9% |
| FY2017 | Dec 31, 2017 | $29.02M | -0.3% |
| FY2016 | Dec 31, 2016 | $29.12M | -16.1% |
| FY2015 | Dec 31, 2015 | $34.73M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.70M | +11.1% |
| Q1 FY2026 | Mar 31, 2026 | $3.92M | +8.0% |
| Q4 FY2025 | Dec 31, 2025 | $3.54M | -8.9% |
| Q3 FY2025 | Sep 30, 2025 | $4.04M | +30.3% |
| Q2 FY2025 | Jun 30, 2025 | $3.33M | -8.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.63M | -3.2% |
| Q4 FY2024 | Dec 31, 2024 | $3.88M | +8.0% |
| Q3 FY2024 | Sep 30, 2024 | $3.10M | -20.2% |
| Q2 FY2024 | Jun 30, 2024 | $3.64M | -33.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.75M | -10.0% |
| Q4 FY2023 | Dec 31, 2023 | $3.59M | -23.2% |
| Q3 FY2023 | Sep 30, 2023 | $3.89M | -13.2% |
| Q2 FY2023 | Jun 30, 2023 | $5.46M | +41.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.17M | -14.3% |
| Q4 FY2022 | Dec 31, 2022 | $4.67M | +2.9% |
| Q3 FY2022 | Sep 30, 2022 | $4.48M | +2.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.87M | -18.1% |
| Q1 FY2022 | Mar 31, 2022 | $4.87M | -9.3% |
| Q4 FY2021 | Dec 31, 2021 | $4.54M | -7.5% |
| Q3 FY2021 | Sep 30, 2021 | $4.37M | -2.8% |
| Q2 FY2021 | Jun 30, 2021 | $4.72M | +6.4% |
| Q1 FY2021 | Mar 31, 2021 | $5.36M | +33.8% |
| Q4 FY2020 | Dec 31, 2020 | $4.91M | +11.4% |
| Q3 FY2020 | Sep 30, 2020 | $4.49M | -40.8% |
| Q2 FY2020 | Jun 30, 2020 | $4.44M | -27.5% |
| Q1 FY2020 | Mar 31, 2020 | $4.01M | -39.6% |
| Q4 FY2019 | Dec 31, 2019 | $4.41M | -50.5% |
| Q3 FY2019 | Sep 30, 2019 | $7.60M | -11.4% |
| Q2 FY2019 | Jun 30, 2019 | $6.13M | -36.9% |
| Q1 FY2019 | Mar 31, 2019 | $6.63M | -19.1% |
| Q4 FY2018 | Dec 31, 2018 | $8.90M | -3.1% |
| Q3 FY2018 | Sep 30, 2018 | $8.57M | +19.5% |
| Q2 FY2018 | Jun 30, 2018 | $9.71M | +43.1% |
| Q1 FY2018 | Mar 31, 2018 | $8.20M | +39.6% |
| Q4 FY2017 | Dec 31, 2017 | $9.19M | +44.4% |
| Q3 FY2017 | Sep 30, 2017 | $7.18M | +1.4% |
| Q2 FY2017 | Jun 30, 2017 | $6.79M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.87M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.36M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.08M | – |
See a number that looks wrong?